Further to our intimation dated January 7, 2021, in relation to execution of a Share Subscription Agreement ('SSA') and a Shareholders' Agreement ('SHA') between Biocon Limited (the 'Company'), Biocon Biologics Limited ('BBL'), existing investors of BBL and Beta Oryx Limited, a wholly owned subsidiary of ADQ (the 'Investor') as applicable, we wish to inform you that the subscription money aggregating to ~Rs. 555 Crores have been received by BBL from the Investor. Consequently, today the Board of BBL has approved allotment of 1,97,99,305 (One Crore Ninety Seven Lakhs Ninety Nine Thousand Three Hundred Five) equity shares at face value of Rs. 10/- (Indian Rupees Ten only) each at an issue price of Rs. 280.31 (Indian Rupees Two Hundred and Eighty and Paisa Thirty One only) per share including a premium of Rs. 270.31 (Indian Rupees Two Hundred and Seventy and Paisa Thirty One only) per share to the Investor.